| | | | | | | | Welcome to Editors' (re)View, where the Pharma Manufacturing editors handpick notable pharma world happenings that deserve some extra consideration. See what you may have missed this week in pharma. |
|
|
|
| |
| | |
|
|
| | | | | The company is investigating deaths from pneumonitis and pleural effusion, but a phase 3 trial is still on the table. |
|
|
| After FTC hurdles caused Sanofi to abandon its $755 million plan to buy the phase 1 drug, Shionogi has swooped in to pick up the promising asset. |
|
|
|
| |
| | |
|
|
| | | | Sponsored | | Dive into the nuances of data integrity as experts from Blue Mountain and Barry-Wehmiller Design Group discuss the challenges organizations face and how they overcome them |
|
|
|
| |
| | |
|
|
| | |
|
| | |
|
